Dermatology · Phase 2-3 · pulled 2026-11-06

Psoriasis: trial sites and investigators

25 sites and 10 investigators from 300 completed and terminated Phase 2-3 trials of psoriasis (last 12 years), plus 115 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Psoriasis: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	Lynderm Research Inc. Markham, Canada · 6 spellings merged	29 26 completed, 3 terminated	NCT05172726 NCT04036435 NCT06973291 6 trials with titles NCT05172726 Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects completed 2026-10-14 NCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis completed 2026-07-21 NCT06973291 A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis completed 2026-04-22 NCT06586112 A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis completed 2025-11-20 NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period completed 2025-11-07 NCT06602219 A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis completed 2025-09-04	2026-10-14	8 NCT06220604 NCT06095102 NCT06934226 NCT07914231	91
2	Texas Dermatology and Laser Specialists San Antonio, United States · 15 spellings merged	28 25 completed, 3 terminated	NCT04036435 NCT06588283 NCT06973291 6 trials with titles NCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis completed 2026-07-21 NCT06588283 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight completed 2026-06-01 NCT06973291 A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis completed 2026-04-22 NCT06588738 A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 completed 2025-12-18 NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period completed 2025-11-07 NCT06088043 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment completed 2025-10-22	2026-07-21	11 NCT06143878 NCT06220604 NCT06095115 NCT06095102	91
3	First OC Dermatology Fountain Valley, United States · 8 spellings merged	26 23 completed, 3 terminated	NCT05172726 NCT06588283 NCT06973291 6 trials with titles NCT05172726 Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects completed 2026-10-14 NCT06588283 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight completed 2026-06-01 NCT06973291 A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis completed 2026-04-22 NCT06586112 A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis completed 2025-11-20 NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period completed 2025-11-07 NCT06088043 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment completed 2025-10-22	2026-10-14	9 NCT06143878 NCT06095115 NCT06934226 NCT07116967	89
4	Dawes Fretzin Clinical Research Group, LLC Indianapolis, United States · 5 spellings merged	25 22 completed, 3 terminated	NCT05172726 NCT06088199 NCT06588283 6 trials with titles NCT05172726 Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects completed 2026-10-14 NCT06088199 A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis completed 2026-08-12 NCT06588283 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight completed 2026-06-01 NCT06973291 A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis completed 2026-04-22 NCT06088043 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment completed 2025-10-22 NCT05272150 Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis completed 2025-05-30	2026-10-14	6 NCT06143878 NCT06095115 NCT06095102 NCT07116967	91
5	Clinical Science Institute Santa Monica, United States	22 20 completed, 2 terminated	NCT06088199 NCT04036435 NCT06602219 6 trials with titles NCT06088199 A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis completed 2026-08-12 NCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis completed 2026-07-21 NCT06602219 A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis completed 2025-09-04 NCT05272150 Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis completed 2025-05-30 NCT06176768 A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis completed 2025-05-06 NCT06039189 Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis completed 2025-04-14	2026-08-12	2 NCT06143878 NCT06095115	91
6	K. Papp Clinical Research Waterloo, Canada · 5 spellings merged	22 20 completed, 2 terminated	NCT06039189 NCT05268016 NCT04761627 6 trials with titles NCT06039189 Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis completed 2025-04-14 NCT05268016 Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis completed 2023-05-31 NCT04761627 A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis completed 2023-02-28 NCT04607980 A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis completed 2022-06-03 NCT03168256 CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis completed 2022-04-27 NCT03777436 An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis completed 2022-02-09	2025-04-14	0	93
7	Peking University Third Hospital Beijing, China · 8 spellings merged	19 18 completed, 1 terminated	NCT07314060 NCT07712731 NCT07008547 6 trials with titles NCT07314060 A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis terminated 2026-07-30 Stop reason on the record: “Due to the company's strategic adjustment in product portfolio, this study has been voluntarily terminated.” NCT07712731 HPP737 in Adult Patients With Plaque Psoriasis completed 2026-04-01 NCT07008547 To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis completed 2026-03-09 NCT06122649 A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) completed 2025-12-05 NCT06477237 Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis completed 2025-10-31 NCT06088043 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment completed 2025-10-22	2026-07-30	17 NCT07129382 NCT04882098 NCT06095115 NCT06878404	99
8	Center for Clinical Studies Webster, United States · 10 spellings merged	19 18 completed, 1 terminated	NCT04036435 NCT06108544 NCT06602219 6 trials with titles NCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis completed 2026-07-21 NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period completed 2025-11-07 NCT06602219 A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis completed 2025-09-04 NCT06073119 A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis completed 2024-12-11 NCT05896527 A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis completed 2024-03-25 NCT05364554 A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis completed 2023-09-29	2026-07-21	8 NCT06143878 NCT06220604 NCT06095115 NCT06095102	93
9	Center for Clinical Studies Houston, United States · 10 spellings merged	19 18 completed, 1 terminated	NCT04036435 NCT06586112 NCT05272150 6 trials with titles NCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis completed 2026-07-21 NCT06586112 A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis completed 2025-11-20 NCT05272150 Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis completed 2025-05-30 NCT06176768 A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis completed 2025-05-06 NCT06039189 Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis completed 2025-04-14 NCT03897075 Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis completed 2025-01-30	2026-07-21	7 NCT06143878 NCT06095115 NCT06095102 NCT06934226	92
10	DermMedica Sp. z o.o. Wroclaw, Poland · 13 spellings merged	19 16 completed, 3 terminated	NCT04036435 NCT06588738 NCT06108544 6 trials with titles NCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis completed 2026-07-21 NCT06588738 A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 completed 2025-12-18 NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period completed 2025-11-07 NCT04493424 A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab terminated 2023-05-15 Stop reason on the record: “Sponsor decision” NCT05194839 A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) terminated 2023-03-06 Stop reason on the record: “Due to safety findings in ongoing Phase 2 trials.” NCT04761627 A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis completed 2023-02-28	2026-07-21	9 NCT06143878 NCT04882098 NCT06095115 NCT06878404	95
11	Solumed Centrum Medyczne Poznan, Poland · 16 spellings merged	19 17 completed, 2 terminated	NCT04036435 NCT04936308 NCT06108544 6 trials with titles NCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis completed 2026-07-21 NCT04936308 Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent completed 2026-07-02 NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period completed 2025-11-07 NCT05071664 A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis completed 2024-08-06 NCT05637515 Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity completed 2023-09-19 NCT03926195 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis completed 2023-05-10	2026-07-21	8 NCT06143878 NCT06095115 NCT06095102 NCT06934226	90
12	Renstar Medical Research Ocala, United States · 3 spellings merged	19 18 completed, 1 terminated	NCT06588283 NCT06588738 NCT06088043 6 trials with titles NCT06588283 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight completed 2026-06-01 NCT06588738 A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 completed 2025-12-18 NCT06088043 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment completed 2025-10-22 NCT06602219 A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis completed 2025-09-04 NCT03897075 Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis completed 2025-01-30 NCT05364554 A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis completed 2023-09-29	2026-06-01	5 NCT06143878 NCT06934226 NCT07116967 NCT06550076	93
13	Total Skin and Beauty Dermatology Center, PC Birmingham, United States · 7 spellings merged	18 14 completed, 4 terminated	NCT04036435 NCT06588283 NCT06588738 6 trials with titles NCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis completed 2026-07-21 NCT06588283 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight completed 2026-06-01 NCT06588738 A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 completed 2025-12-18 NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period completed 2025-11-07 NCT05272150 Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis completed 2025-05-30 NCT06039189 Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis completed 2025-04-14	2026-07-21	2 NCT06550076 NCT06846541	88
14	Xiangya Hospital of Central South University Changsha, China · 11 spellings merged	17 16 completed, 1 terminated	NCT07357831 NCT07314060 NCT06592274 6 trials with titles NCT07357831 A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects completed 2026-08-19 NCT07314060 A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis terminated 2026-07-30 Stop reason on the record: “Due to the company's strategic adjustment in product portfolio, this study has been voluntarily terminated.” NCT06592274 A Phase 2 Study of HB0017 in Psoriasis Patients completed 2026-04-10 NCT07712731 HPP737 in Adult Patients With Plaque Psoriasis completed 2026-04-01 NCT06542614 Treatment of Moderate to Severe Plaque Psoriasis completed 2025-12-06 NCT06122649 A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) completed 2025-12-05	2026-08-19	7 NCT06878404 NCT07321873 NCT06807424 NCT07724366	99
15	DermEdge Research Mississauga, Canada · 8 spellings merged	17 16 completed, 1 terminated	NCT04036435 NCT06586112 NCT06108544 6 trials with titles NCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis completed 2026-07-21 NCT06586112 A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis completed 2025-11-20 NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period completed 2025-11-07 NCT06602219 A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis completed 2025-09-04 NCT05896527 A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis completed 2024-03-25 NCT05375955 A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. completed 2023-07-31	2026-07-21	5 NCT06220604 NCT07914231 NCT07116967 NCT06550076	93
16	Toronto Research Centre Toronto, Canada · 8 spellings merged	17 17 completed, 0 terminated	NCT04036435 NCT06588738 NCT06108544 6 trials with titles NCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis completed 2026-07-21 NCT06588738 A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 completed 2025-12-18 NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period completed 2025-11-07 NCT06088043 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment completed 2025-10-22 NCT05272150 Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis completed 2025-05-30 NCT06039189 Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis completed 2025-04-14	2026-07-21	3 NCT07116967 NCT06550076 NCT06846541	93
17	Psoriasis Treatment Center of Central New Jersey East Windsor, United States · 2 spellings merged	17 14 completed, 3 terminated	NCT06588283 NCT06108544 NCT05272150 6 trials with titles NCT06588283 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight completed 2026-06-01 NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period completed 2025-11-07 NCT05272150 Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis completed 2025-05-30 NCT06176768 A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis completed 2025-05-06 NCT04493424 A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab terminated 2023-05-15 Stop reason on the record: “Sponsor decision” NCT04761627 A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis completed 2023-02-28	2026-06-01	1 NCT06550076	88
18	Virginia Clinical Research, Inc. Norfolk, United States · 4 spellings merged	17 15 completed, 2 terminated	NCT06588283 NCT06108544 NCT05896527 6 trials with titles NCT06588283 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight completed 2026-06-01 NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period completed 2025-11-07 NCT05896527 A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis completed 2024-03-25 NCT05375955 A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. completed 2023-07-31 NCT05223868 A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis completed 2022-12-15 NCT03777436 An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis completed 2022-02-09	2026-06-01	1 NCT06550076	91
19	Universitatsklinikum Frankfurt Frankfurt am Main, Germany · 3 spellings merged	17 15 completed, 2 terminated	NCT06586112 NCT06602219 NCT03818035 6 trials with titles NCT06586112 A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis completed 2025-11-20 NCT06602219 A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis completed 2025-09-04 NCT03818035 A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis completed 2025-01-07 NCT05896527 A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis completed 2024-03-25 NCT05364554 A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis completed 2023-09-29 NCT04493424 A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab terminated 2023-05-15 Stop reason on the record: “Sponsor decision”	2025-11-20	2 NCT03886246 NCT06846541	86
20	Modern Research Associates Dallas, United States · 3 spellings merged	16 15 completed, 1 terminated	NCT06588283 NCT06588738 NCT06108544 6 trials with titles NCT06588283 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight completed 2026-06-01 NCT06588738 A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 completed 2025-12-18 NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period completed 2025-11-07 NCT05272150 Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis completed 2025-05-30 NCT06039189 Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis completed 2025-04-14 NCT05364554 A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis completed 2023-09-29	2026-06-01	5 NCT06143878 NCT06934226 NCT07116967 NCT06550076	92
21	Dermatrials Research Hamilton, Canada · 4 spellings merged	16 16 completed, 0 terminated	NCT06973291 NCT06586112 NCT06108544 6 trials with titles NCT06973291 A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis completed 2026-04-22 NCT06586112 A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis completed 2025-11-20 NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period completed 2025-11-07 NCT06602219 A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis completed 2025-09-04 NCT06039189 Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis completed 2025-04-14 NCT05896527 A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis completed 2024-03-25	2026-04-22	4 NCT06143878 NCT06934226 NCT06550076 NCT06846541	92
22	Dr. Chih-ho Hong Medical Inc. Surrey, Canada · 6 spellings merged	16 14 completed, 2 terminated	NCT06973291 NCT05272150 NCT06039189 6 trials with titles NCT06973291 A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis completed 2026-04-22 NCT05272150 Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis completed 2025-05-30 NCT06039189 Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis completed 2025-04-14 NCT05073315 A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis completed 2022-12-19 NCT04607980 A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis completed 2022-06-03 NCT03556202 A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) terminated 2022-02-07 Stop reason on the record: “The study was terminated due to a strategic business decision made by the Sponsor.”	2026-04-22	2 NCT06220604 NCT06095115	95
23	Innovaderm Research Inc. Montreal, Canada · 5 spellings merged	15 13 completed, 2 terminated	NCT05172726 NCT06588738 NCT05364554 6 trials with titles NCT05172726 Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects completed 2026-10-14 NCT06588738 A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 completed 2025-12-18 NCT05364554 A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis completed 2023-09-29 NCT05375955 A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. completed 2023-07-31 NCT04493424 A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab terminated 2023-05-15 Stop reason on the record: “Sponsor decision” NCT05223868 A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis completed 2022-12-15	2026-10-14	5 NCT06220604 NCT06095115 NCT06095102 NCT06934226	85
24	Dermatology Hospital of Southern Medical University Guangzhou, China · 4 spellings merged	15 14 completed, 1 terminated	NCT07357831 NCT07314060 NCT06592274 6 trials with titles NCT07357831 A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects completed 2026-08-19 NCT07314060 A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis terminated 2026-07-30 Stop reason on the record: “Due to the company's strategic adjustment in product portfolio, this study has been voluntarily terminated.” NCT06592274 A Phase 2 Study of HB0017 in Psoriasis Patients completed 2026-04-10 NCT07712731 HPP737 in Adult Patients With Plaque Psoriasis completed 2026-04-01 NCT06542614 Treatment of Moderate to Severe Plaque Psoriasis completed 2025-12-06 NCT06122649 A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) completed 2025-12-05	2026-08-19	7 NCT07116967 NCT07724366 NCT07250802 NCT07719530	98
25	Shanghai Skin Disease Hospital Shanghai, China · 3 spellings merged	15 14 completed, 1 terminated	NCT07357831 NCT07314060 NCT07712731 6 trials with titles NCT07357831 A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects completed 2026-08-19 NCT07314060 A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis terminated 2026-07-30 Stop reason on the record: “Due to the company's strategic adjustment in product portfolio, this study has been voluntarily terminated.” NCT07712731 HPP737 in Adult Patients With Plaque Psoriasis completed 2026-04-01 NCT06122649 A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) completed 2025-12-05 NCT06088043 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment completed 2025-10-22 NCT06648772 Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study completed 2025-10-15	2026-08-19	9 NCT04882098 NCT06095115 NCT06878404 NCT06807424	98

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Psoriasis: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Jianzhong Zhang Peking University People's Hospital	8	NCT07712731 NCT06477237 NCT06278350 NCT07712705 NCT05536726	PMID 42923801 Rheumatology and immunology research, 2026 · High match PMID 42920534 Frontiers in immunology, 2026 · High match
2	Min Zheng Second Affiliated Hospital, Zhejiang University, School of Medicine	4	NCT05377944 NCT04728360 NCT04102241 NCT03222622	PMID 42716213 The Journal of investigative dermatology, 2026 · High match PMID 42701320 The British journal of dermatology, 2026 · High match PMID 42372782 The Lancet. Rheumatology, 2026 · High match
3	Roman Ivanov Biocad	3	NCT03598751 NCT03390101 NCT02762955	No paper matched at High or Medium confidence
4	Jin h Xu Huashan Hospital	2	NCT06398652 NCT05536726	PMID 39012666 Aging and disease, 2025 · High match PMID 33177393 Chinese medical journal, 2021 · High match PMID 33060370 Chinese medical journal, 2021 · High match
5	Benjamin D Ehst Oregon Medical Research Center	2	NCT05283135 NCT04603027	PMID 42208526 Immunity, 2026 · High match PMID 41381642 Nature communications, 2026 · High match PMID 38813388 Frontiers in medicine, 2024 · High match
6	Hongzhong Jin Peking Union Medical College Hospital	2	NCT04173637 NCT04172233	PMID 42220470 Clinical, cosmetic and investigational dermatology, 2026 · High match PMID 42202956 Journal of the American Academy of Dermatology, 2026 · High match PMID 41982475 Journal of inflammation research, 2026 · High match
7	Steven Feldman Wake Forest University Health Sciences	2	NCT04453137 NCT03849404	PMID 42598996 Expert opinion on biological therapy, 2026 · High match PMID 42552595 Expert opinion on pharmacotherapy, 2026 · High match PMID 42149685 Expert opinion on drug safety, 2026 · High match
8	Chuanjian Lu Guangdong Provincial Hospital of Traditional Chinese Medicine	2	NCT03392311 NCT03265613	PMID 42962484 International immunopharmacology, 2026 · High match PMID 42656768 Frontiers in psychiatry, 2026 · High match PMID 42597665 Frontiers in immunology, 2026 · High match
9	Zhixiu Lin Hong Kong Institute of Integrative Medicine	1	NCT05295979	No paper matched at High or Medium confidence
10	Oksana A. Markova JSC GENERIUM	1	NCT06488664	No paper matched at High or Medium confidence

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.